Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
about
Recent advances of highly selective CDK4/6 inhibitors in breast cancerEmerging therapies for breast cancerPalbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein.Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells.Differences Are Important: Breast Cancer Therapy in Different Ethnic GroupsSolute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.Optimization and validation of RP-HPLC method for simultaneous estimation of palbociclib and letrozole.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: a Japanese phase II study.Updates on managing advanced breast cancer with palbociclib combination therapyThe Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
P2860
Q33602076-5F10C620-EFC3-492F-B9A2-C8F348980C0FQ33617949-D1BB0754-A067-4B68-A323-174CE4BB3A04Q37723172-E1D9E599-A843-42B5-8825-89A28B735D75Q38662999-3E1A2F6E-66E0-4F47-8B7E-BF3CEA29D8D8Q38666834-2D7A4F97-7CE4-4EC8-B633-07F127FD468DQ42346622-A1050757-7434-4846-8E8A-30FBA8EA7EAAQ47259025-567DAA2C-C168-4F8B-BAF6-814D2EACE87DQ48239334-B22E155A-C579-40FB-83E2-16BBBEDEDF97Q48512373-D7A7C93B-729A-4553-B5E8-EF1E0F9CADB3Q49171317-C7117E6B-DA76-4102-A63E-59C4BAA58EECQ49970470-CD72C447-CC83-49D0-84F4-CDB9B5464AB7Q57106487-6E5CFBE2-8B88-49F6-8B37-D178C99AFCA9Q57293716-CADF173B-D753-4CDB-A2AC-8381BE301631
P2860
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I study of palbociclib, ...... nhibitor, in Japanese patients
@en
Phase I study of palbociclib, ...... hibitor, in Japanese patients.
@nl
type
label
Phase I study of palbociclib, ...... nhibitor, in Japanese patients
@en
Phase I study of palbociclib, ...... hibitor, in Japanese patients.
@nl
prefLabel
Phase I study of palbociclib, ...... nhibitor, in Japanese patients
@en
Phase I study of palbociclib, ...... hibitor, in Japanese patients.
@nl
P2093
P2860
P356
P1433
P1476
Phase I study of palbociclib, ...... nhibitor, in Japanese patients
@en
P2093
Hirofumi Mukai
Kan Yonemori
Kenji Tamura
Makoto Kodaira
Masaoki Sasaki
Noboru Yamamoto
Satoshi Hashigaki
Takashi Nagasawa
Takayuki Yoshino
Yoichi Naito
P2860
P304
P356
10.1111/CAS.12932
P50
P577
2016-05-11T00:00:00Z